Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
All set to reveal its first anti-cancer and pro-immunity product in April 2022
Noida-based Zeon Lifesciences is dedicating its R&D efforts to the preventive measures of Cancer. R&D experts at Zeon, with a multidirectional approach, have developed science-based botanical products with different formulations for the prevention and management of cancer.
The company is set to launch its first anti-cancer and pro-immunity product in April 2022, in the first quarter. The product is under rigorous regulatory compliance licensing processes. These products will be made available in the form of sachets and capsules for cancer patients.
By 2023, the products will be across PAN India, and global markets will be targeted to expand nutraceutical wellness rotation around the world.
Suresh Garg, Founder and MD, Zeon Lifesciences, said, “A study by the National Center for Biotechnology Information has shown that Nutraceuticals, functional foods and supplemental micronutrients have the potential to reduce cancer cell growth, inhibiting cell proliferation and inducing cancer cell apoptosis. Nutraceuticals is a new ray of hope to prevent chronic illness.”